2021-01-08,COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan  Metro System Line 2 by Physician-Scientist Dr. Steven Quay
2021-01-06,Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
2020-12-17,Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market
2020-12-09,Here's Why We're A Bit Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation
2020-12-08,Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering
2020-11-17,Foxx Life Sciences Announces Opening of New Asia Headquarters in India
2020-11-13,Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
2020-11-10,Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
2020-10-28,"New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic"
2020-10-19,Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
2020-10-07,"Registration Is Now Open For Atossa Therapeutics Tribe Public Webinar Presentation and Q&A Event On October 13, 2020"
2020-10-02,"Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, ""Stay Safe: A Physician's Guide to Survive Coronavirus,"" to the White House Upon the News of COVID in the First Family"
2020-09-21,"Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020"
2020-09-17,Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
2020-09-14,"Physician-Scientist Dr. Steven Quay's ""Stay Safe: A Physician's Guide to Survive Coronavirus"" Reaches #1 on Five Amazon Bestsellers Lists"
2020-09-08,Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and Survive Coronavirus
2020-09-01,Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19
2020-08-31,LD Micro: 360 Companies - Set to Present this Week
2020-08-31,Penny Stocks to Buy Using Technical Analysis for September 2020
2020-08-26,"Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020"
2020-08-17,Atossa Therapeutics Announces  Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19
2020-08-13,Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
2020-08-05,LD Micro Announces Preliminary List of Presenters for the LD-500.
2020-08-03,Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray  Being Developed to Treat COVID-19
2020-07-30,Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
2020-07-27,"Registration Is Now Open for Atossa Therapeutics Tribe Public Webinar Presentation and Q&A Event on July 30, 2020"
2020-07-21,Atossa Stock at $8 a Share? This 5-Star Analyst Thinks Its Possible
2020-07-16,"Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossas Second COVID-19 Therapeutic Development Program"
2020-07-15,Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
2020-07-08,"Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls"
2020-06-13,Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?
2020-06-11,"Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201"
2020-06-05,Potential Life Saving COVID-19 Survival Manual Removed from Amazon Kindle Store Three Days before Official Launch
2020-05-29,SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January 2020
2020-05-28,"Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study"
2020-05-20,Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
2020-05-13,Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
2020-05-07,Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment
2020-05-07,Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs
2020-04-27,Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study
2020-04-22,Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says Buy
2020-04-20,Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
2020-04-17,"COVID-19 Cease Fire for the United States on April 23, 2020 and successful Opening Up America Again initiative predicted"
2020-04-16,Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
2020-04-02,Atossa Therapeutics Announces Clinical Progress
2020-03-30,New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients
2020-03-26,Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update
2020-03-13,Atossa Therapeutics Announces Upcoming Meeting with FDA
2020-03-02,"Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density"
2020-02-05,"Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference"
2020-02-04,"Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day ""Transforming Breast Cancer Treatment"""
2020-01-22,Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020
2020-01-06,"Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc."
2019-12-19,Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
2019-12-16,Is Atossa Genetics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?
2019-12-05,"Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019"
2019-11-13,Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update
2019-10-23,Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
2019-10-16,Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology
2019-10-15,"Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia"
2019-09-30,Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen
2019-09-06,Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference
2019-09-03,Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet
2019-08-13,Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update
2019-07-30,Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk
2019-07-17,Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests
2019-07-11,Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated
2019-06-28,"A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019"
2019-06-27,Atossa Genetics Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
2019-06-19,Some Atossa Genetics (NASDAQ:ATOS) Shareholders Have Copped A 99% Share Price Wipe Out
2019-05-30,"Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019"
2019-05-13,Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update
2019-04-30,"""The Digital Economy & World Markets"""
2019-04-25,Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit
2019-04-22,Reducing This Amino Acid May Aid In Fight Against Breast Cancer
2019-04-22,"Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019"
2019-03-28,Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
2019-03-27,"""Bull Market Hopping?"""
2019-03-26,Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
2019-03-18,Atossa Genetics Announces Receipt of $10 Million
2019-03-14,What Type Of Shareholder Owns Atossa Genetics Inc.s (NASDAQ:ATOS)?
2019-03-14,Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
2019-03-14,Atossa Genetics Announces FDA Approval of Oral Endoxifen for Expanded Access as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
2019-02-27,"""On Fed's Wings"" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter"
2019-02-07,Atossa Genetics Reports Results From Expanded Access Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
2019-02-04,Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force
2019-01-30,Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter
2019-01-28,Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019
2019-01-10,Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics
2019-01-09,4 Healthcare Stocks Looking To Set January Highs
2019-01-09,Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen
2018-12-28,"Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics  What Drives Growth in Today's Competitive Landscape"
2018-12-19,"""The Roller Coaster Ride Continues"""
2018-12-07,Edison issues outlook on Atossa Genetics (ATOS)
2018-12-03,Atossa Genetics Announces FDA Approval  of Endoxifen for Expanded Access as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
2018-11-21,''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter
2018-11-13,Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update
2018-10-25,"Report: Exploring Fundamental Drivers Behind Atossa Genetics, Titan International, Olympic Steel, L Brands, Sysco, and TiVo  New Horizons, Emerging Trends, and Upcoming Developments"
2018-10-18,"""...Amidst Market Volatility"" Vista Partners' October Macroeconomic & Investment Monthly Newsletter"
2018-10-11,Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density
